Grand Rounds July 29, 2022: Effect of Early Treatment With Single-Dose Pegylated Interferon Lambda Among Patients With COVID-19: Results From The TOGETHER Trial (Edward Mills, PhD, FRCP; Jeffrey S. Glenn, MD, PhD)
Rethinking Clinical Trials
AUGUST 4, 2022
The unvaccinated and early treatment population saw a 89% risk reduction, which is very similar to what was identified in the Paxlovid trial. In the same population, if treated early there was a 65% reduction for the primary outcome and hospitalization or death due to COVID-19. Discussion Themes. Learn more about TOGETHER.
130 
Let's personalize your content